Biohit Oyj stock exchange release October 24, 2016 at 09:30 am local time (EEST)
Biohit Oyj’s Chinese joint venture Biohit HealthCare (Hefei) Co. Ltd production facility has passed official test requirements and has been granted a license enabling production and sales of products. Biohit HealthCare (Hefei) Co. Ltd will start manufacturing of the globally unique GastroPanel®-products developed by Biohit Oyj for the Chinese market, and the first shipments will go to fill orders relating to the ongoing gastric cancer risk screening study which has been expanded to cover over 150 hospitals and expected to be concluded by the end of 2016 on part of the patient screening. The study will continue with statistical data analysis and reporting from various municipalities and hospitals that have taken part in the study. The reporting and analysis phase is expected to be completed during 2017. The results of the analysis will determine if a population based screening program is feasible. In the meantime sales of GastroPanel®-tests has continued in the 14 provinces where price approval has been granted. Biohit Oyj will supply the necessary raw materials and reagents used in production.
Exhibitor Data Sheet